The clinical significance of circulating microparticles
concerning thrombosis in BCR/ABL1-negative myeloproliferative
neoplasms

J 2021

The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ, Miroslav PENKA et. al.

Basic information

Original name

The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms

Authors

ASWAD, Mohamed Hussam (760 Syrian Arab Republic, guarantor, belonging to the institution), Jarmila KISSOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Lucie ŘÍHOVÁ (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution)

Edition

In vivo, Athens, International Institute of Anticancer Research, 2021, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.406

RIV identification code

RIV/00216224:14110/21:00122607

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/invivo.12632

UT WoS

000711693300017

Keywords in English

Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea

Abstract

V originále

Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs’ procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.

Citovat

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ and Miroslav PENKA. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. In vivo. Athens: International Institute of Anticancer Research, 2021, vol. 35, No 6, p. 3345-3353. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12632.

@article{1798682,
   author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Ovesná, Petra and Říhová, Lucie and Penka, Miroslav},
   article_location = {Athens},
   article_number = {6},
   doi = {http://dx.doi.org/10.21873/invivo.12632},
   keywords = {Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms},
   url = {https://iv.iiarjournals.org/content/35/6/3345},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1798682
AU  - Aswad, Mohamed Hussam - Kissová, Jarmila - Ovesná, Petra - Říhová, Lucie - Penka, Miroslav
PY  - 2021
TI  - The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms
JF  - In vivo
VL  - 35
IS  - 6
SP  - 3345-3353
EP  - 3345-3353
PB  - International Institute of Anticancer Research
SN  - 0258851X
KW  - Myeloproliferative neoplasm
KW  - microparticle
KW  - procoagulant activity
KW  - thrombosis
KW  - anagrelide
KW  - hydroxyurea
UR  - https://iv.iiarjournals.org/content/35/6/3345
N2  - Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs’ procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
ER  -

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ and Miroslav PENKA. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. \textit{In vivo}. Athens: International Institute of Anticancer Research, 2021, vol.~35, No~6, p.~3345-3353. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12632.

Detailed Information on Publication Record